亿帆医药：上半年净利润3.04亿元 同比增长19.91%

Core Viewpoint - Yifan Pharmaceutical (002019) reported a slight revenue growth of 0.11% year-on-year for the first half of 2025, with significant profit growth driven by innovative drug sales [1] Financial Performance - The company achieved a revenue of 2.635 billion yuan in the first half of 2025 [1] - Net profit attributable to shareholders reached 304 million yuan, reflecting a year-on-year increase of 19.91% [1] Business Segments - Sales revenue from innovative drugs surged by 169.57% year-on-year, contributing to a rapid increase in the proportion of high-margin business [1] - The growth in innovative drug sales was identified as the core driver for the substantial improvement in the company's non-recurring profit margin [1]